Secretin and Cholecystokin/Pancreozymin in Combination in the Inhibition of Gastric Acid Secretion

Total Page:16

File Type:pdf, Size:1020Kb

Secretin and Cholecystokin/Pancreozymin in Combination in the Inhibition of Gastric Acid Secretion Gut: first published as 10.1136/gut.12.12.968 on 1 December 1971. Downloaded from Gut, 1971, 12, 968-972 Secretin and cholecystokin/pancreozymin in combination in the inhibition of gastric acid secretion B. S. BEDI, H. T. DEBAS, A. E. 0. WASUNNA, B. F. BUXTON, AND I. E. GILLESPIE From the University Department ofSurgery, Western Infirmary, Glasgow SUMMARY Both secretin, and the single substance which possesses both cholecystokinin and pancreozymin activity, have been shown to inhibit gastric acid secretory responses. Since potentiation may occur between pairs of stimulants of gastric secretion, the effects of combining secretin and cholecystokiniu/pancreozymin have been studied in Heidenhain pouches stimulated by contin- uous intravenous pentagastrin. Evidence suggesting potentiation between these two inhibitor agents is presented. Inhibition of gastric acid secretion is caused when Materials and Methods the mucosa of the upper small intestine is bathed either by fat (Feng, Hou, and Lim, 1929), acid The observations were made on three dogs with (Sokolov, 1904) or hyperosmolar solutions (Konturek Heidenhain type fundic pouches, the gastrointestinal and Grossman, 1965). The studies of Andersson tract otherwise being intact. The dogs' weights were (1960) suggest that the inhibition caused by acid in between 15 and 20 kg and all operative procedures the duodenum is mediated by a humoral agent. had been completed more than three months before There is therefore interest in the possible inhibitor the present experiments. http://gut.bmj.com/ properties on gastric acid secretion of extracts Acid secretion from the Heidenhain pouch was prepared from duodenal mucosa (Jorpes, 1968). stimulated by a continuous constant-rate intravenous Under certain experimental conditions in dogs, infusion of pentagastrin at a dose which gave the relatively pure secretin (Gillespie and Grossman, maximal acid response from the Heidenhain pouch. 1964a; Wormsley and Grossman, 1964) and During each experiment the secretion from the relatively pure cholecystokinin/pancreozymin Heidenhain pouch was collected continuously, and and (Gillespie Grossman, 1964, Bedi, Govaerts, every 15 minutes the volume was measured in milli- on October 1, 2021 by guest. Protected copyright. Master, and Gillespie, 1967) have been demonstrated litres and the acid concentration estimated by to inhibit Heidenhain pouch acid responses to titration against 0 01N sodium hydroxide with stimulation by gastrin and it has been suggested phenol red indicator, end-point 6.8 to 8.4. Acid that these agents may in fact be the principal outputs were derived from multiplication of the mediators of the inhibition. volume and concentration values. A plateau of acid There is evidence of potentiation at the level of the secretion from the Heidenhain pouch to the intra- acid-producing cells between pairs of stimulants, eg, venous infusion of pentagastrin was considered to gastrin extract and stable choline ester (Gillespie have been achieved when four consecutive 15- and Grossman, 1964b), and gastrin and histamine minute acid outputs varied less than 15 %. (Passaro, Gillespie, and Grossman, 1964). Bedi, The relatively pure secretin and cholecystokinin/ Debas, Gillespie, and Gillespie (1971) have also pancreozymin preparations were purchased from shown potentiation between bile salts and acetylcho- Professor Jorpes of the Karolinska Institute, line in the release of gastrin from the pyloric antrum. Stockholm. The substance with both cholecystokinin It is possible that potentiation may also exist between and pancreozymin activities will hereafter be referred various inhibitors of gastric acid secretion. The to simply as cholecystokinin. present experiments were therefore designed to At the start of each experiment two continuous explore the possibility that both secretin and intravenous infusions were established, one to infuse cholecystokinin/pancreozymin acting together may the pentagastrin in 09 % saline solution, and the result in facilitated or potentiated inhibition. other with 0 9% saline for the subsequent infusion of Received for publication 17 September 1971. the inhibitor agents. Once a plateau acid response to 968 Gut: first published as 10.1136/gut.12.12.968 on 1 December 1971. Downloaded from Secretin and cholecystokinin/pancreozymin in combination in the inhibition ofgastric acid secretion 969 pentagastrin had been established, the secretin or minutes, after which there was a return to control cholecystokinin, or both combined, were given levels. through the second continuous constant rate intra- venous infusion set over a one-hour period. EFFECT OF CHOLECYSTOKININ ALONE ON THE Differences between test and control mean values ACID RESPONSE OF THE HEIDENHAIN POUCH TO for each 15-minute period were tested for statistical PENTAGASTRIN significance by Student's t-test for paired values. The results of two experiments in each of the three dogs are shown in Figure 2. Seventy-five clinical units Results of cholecystokinin infusion over one hour caused a significant reduction of the acid response of the EFFECT OF SECRETIN ALONE ON THE ACID Heidenhain pouch to pentagastrin for 90 minutes. RESPONSE OF THE POUCH TO PENTAGASTRIN Figure 1 shows the effect of75 clinical units ofsecretin infusion on the acid response of the Heidenhain HEIDENHAIN POUCH DOGS pouch to the maximal dose of pentagastrin. The inhibition of acid secretion occurred rapidly after the PENTAGASTRIN 40-80Mg/hr W/ start of the secretin infusion, being present within C IOLECYSTOKININ 15 minutes, and statistically significant for 105 75 units/hrI ACID OUTPUT as % of CONTROL HEIDENHAIN POUCH DOGS 100% = 3.44 mEq/ hr PENTAGASTRIN 40-80Aag/hr 110,1 SECRETIN 75 units/hr ACID OUTPUT as % of CONTROL 100 % = 3-88 mEq/hr http://gut.bmj.com/ on October 1, 2021 by guest. Protected copyright. 0 2 4 6 8 10 12 15 MINUTE INTERVALS 6 Expts Fig. 2 The effects ofan infusion ofcholecystokinin on xx Heidenhain pouch secretion stimulated by intravenous _1_3 Dogs Control infusion ofpentagastrin. .-------.Continuous line shows the means and shaded areas the I I 1 1 1 1 1 1 1 1 i standard errors of these means for each 15-minute acid 0 output. The crosses denote statistically significant 2 4 6 8 10 12 difference from control levels; two crosses indicate 15 MINUTE INTERVALS p < 0.01 and one cross P < 0.05. Fig. 1 The effects ofan infusion ofsecretin on In order to determine whether the two agents given Heidenhain pouch secretion stimulated by intravenous simultaneously might potentiate each other in the infusion ofpentagastrin. acid secretion it was to infuse Continuous line shows the means and shaded areas the inhibition of necessary standard errors ofthese means for each 15-minute acid smaller doses than those used in these foregoing output. The crosses denote statistically significant experiments. It was decided to establish the doses of differencefrom control levels; two crosses indicate secretin and of cholecystokinin which, given p<0-01. separately, would bejust subthreshold for inhibition Gut: first published as 10.1136/gut.12.12.968 on 1 December 1971. Downloaded from 970 B. S. Bedi, H. T. Debas, A. E. 0. Wasunna, B. F. Buxton, and L E. Gillespie of the acid response to maximal stimulation by give significant inhibition. Therefore 9.5 clinical units pentagastrin, and then observe the effects of simul- of secretin was regarded as a subthreshold dose for taneous infusion of these subthreshold doses of both inhibition. agents. In this way we could apply a criterion for potentiation analogous to that employed for EFFECT OF VARYING DOSES OF CHOLECYSTO- potentiation between two stimulants of secretion, KININ INFUSION ON ACID RESPONSE OF HEIDEN- namely, the response to the combined agents HAIN POUCH TO PENTAGASTRIN exceeding that to twice the dose of either agent The dose-response pattern to cholecystokinin given alone, proposed by Gillespie and Grossman infusion is shown in Figure 4. With this material (1964b), based on the work of Gaddum (1959). HEIDENHAIN POUCH DOGS EFFECT OF VARYING DOSES OF SECRETIN INFUSION ON ACID RESPONSE OF HEIDENHAIN ,PENTAGASTRIN 40- 4g/hr// POUCH TO PENTAGASTRIN In Figure 3 are shown the results of the inhibitor dose-response studies using secretin alone. With CHOLECYSTOKININIfSON i'' progressive reduction in the dose of secretin there was parallel fall in both degree and duration of ACID OUTPUT inhibition of acid output. With 19 units of secretin as % of CONTROL inhibition of the pentagastrin response was still present, but 9.5 clinical units of secretin failed to HEIDENHAIN POUCH DOGS PENTAGASTRIN 40-80Ahr ¶ ISECRETIN r INFUION http://gut.bmj.com/ ACID OUTPUT as % of CONTROL 0 2 4 6 8 10 12 15 MINUTE INTERVALS on October 1, 2021 by guest. Protected copyright. Fig. 4 The eftects of infusion of 75 units (light interrupted line) and 37-5 units (heavy continuous line) ofcholecystokinin on Heidenhain pouch acid response to intravenous infusion ofpentagastrin. Six experiments in three dogsfor each dose studied. __,___ also -there was a reduction in both the degree and duration of inhibition of acid response of the 1 1 1 1 1 1 12 Heidenhain pouch to pentagastrin when smaller -j 2 6 8 1 12 doses were infused. In this instance the subthreshold 1S MINUTE INTERVALS inhibitory dose of cholecystokinin was 19 clinical units. Fig. 3 The effects ofinfusion of 75 units (heavy interrupted line), 37.5 units (light interrupted line), and EFFECT OF SIMULTANEOUS INFUSIONS OF 19 units (heavy continuous line) ofsecretin on Heidenhain ON pouch
Recommended publications
  • Non Conventional Synthetic Strategies of Stapled Peptides: Modulation of Secondary Structures to Optimise Biological Recognition
    PhD THESIS OF THE UNIVERSITY OF CERGY-PONTOISE CO-TUTORED WITH THE UNIVERSITY OF FLORENCE Non conventional synthetic strategies of stapled peptides: modulation of secondary structures to optimise biological recognition presented by : Chiara TESTA PhD discussed on March 26th 2012, Composition of the evaluation committee: Pr. Solange LAVIELLE Rapporteur Pr. Luis MORODER Rapporteur Pr. Anna Maria PAPINI Directrice de thèse Pr. Nadège GERMAIN Directrice de thèse Pr. Paolo ROVERO Directeur de thèse Pr. Michael CHOREV Examinateur Pr. Jacques AUGE Examinateur Pr Andrea GOTI Examinateur Chiara Testa, PhD Thesis Table of contents INTRODUCTION .................................................................................................................. 1 1 Difficult peptide synthesis optimized by microwave-assisted approach: a case study of PTHrP(1–34)NH2 ......................................................................................... 18 1.1 The Parathyroid hormone (PTH) and the Parathyroid hormone-related protein (PTHrP) .................................................................................... 18 1.2 Microwave assisted peptide synthesis .................................................. 20 1.2.1 Thermal effects ..................................................................................... 21 1.2.2 Specific non-thermal effects ................................................................. 22 1.2.3 Modes .................................................................................................... 22 1.3 Synthetic
    [Show full text]
  • The Use of the Calcitonin Minimal Recognition Module for the Design of DOPA-Containing Fibrillar Assemblies
    Nanomaterials 2014, 4, 726-740; doi:10.3390/nano4030726 OPEN ACCESS nanomaterials ISSN 2079-4991 www.mdpi.com/journal/nanomaterials Article The Use of the Calcitonin Minimal Recognition Module for the Design of DOPA-Containing Fibrillar Assemblies Galit Fichman 1,†, Tom Guterman 1,†, Lihi Adler-Abramovich 1 and Ehud Gazit 1,2,* 1 Department of Molecular Microbiology and Biotechnology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 6997801, Israel; E-Mails: [email protected] (G.F.); [email protected] (T.G.); [email protected] (L.A.-A.) 2 Department of Materials Science and Engineering, Iby and Aladar Fleischman Faculty of Engineering, Tel Aviv University, Tel Aviv 6997801, Israel † These authors are equal contributors to this work. * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +972-3-640-7498; Fax: +972-3-640-7499. Received: 3 June 2014; in revised form: 28 July 2014 / Accepted: 8 August 2014 / Published: 20 August 2014 Abstract: Amyloid deposits are insoluble fibrous protein aggregates, identified in numerous diseases, which self-assemble through molecular recognition. This process is facilitated by short amino acid sequences, identified as minimal modules. Peptides corresponding to these motifs can be used for the formation of amyloid-like fibrillar assemblies in vitro. Such assemblies hold broad appeal in nanobiotechnology due to their ordered structure and to their ability to be functionalized. The catechol functional group, present in the non-coded L-3,4-dihydroxyphenylalanine (DOPA) amino acid, can take part in diverse chemical interactions. Moreover, DOPA-incorporated polymers have demonstrated adhesive properties and redox activity.
    [Show full text]
  • Identification of Neuropeptide Receptors Expressed By
    RESEARCH ARTICLE Identification of Neuropeptide Receptors Expressed by Melanin-Concentrating Hormone Neurons Gregory S. Parks,1,2 Lien Wang,1 Zhiwei Wang,1 and Olivier Civelli1,2,3* 1Department of Pharmacology, University of California Irvine, Irvine, California 92697 2Department of Developmental and Cell Biology, University of California Irvine, Irvine, California 92697 3Department of Pharmaceutical Sciences, University of California Irvine, Irvine, California 92697 ABSTRACT the MCH system or demonstrated high expression lev- Melanin-concentrating hormone (MCH) is a 19-amino- els in the LH and ZI, were tested to determine whether acid cyclic neuropeptide that acts in rodents via the they are expressed by MCH neurons. Overall, 11 neuro- MCH receptor 1 (MCHR1) to regulate a wide variety of peptide receptors were found to exhibit significant physiological functions. MCH is produced by a distinct colocalization with MCH neurons: nociceptin/orphanin population of neurons located in the lateral hypothala- FQ opioid receptor (NOP), MCHR1, both orexin recep- mus (LH) and zona incerta (ZI), but MCHR1 mRNA is tors (ORX), somatostatin receptors 1 and 2 (SSTR1, widely expressed throughout the brain. The physiologi- SSTR2), kisspeptin recepotor (KissR1), neurotensin cal responses and behaviors regulated by the MCH sys- receptor 1 (NTSR1), neuropeptide S receptor (NPSR), tem have been investigated, but less is known about cholecystokinin receptor A (CCKAR), and the j-opioid how MCH neurons are regulated. The effects of most receptor (KOR). Among these receptors, six have never classical neurotransmitters on MCH neurons have been before been linked to the MCH system. Surprisingly, studied, but those of most neuropeptides are poorly several receptors thought to regulate MCH neurons dis- understood.
    [Show full text]
  • Natriuretic Peptides in Anxiety and Panic Disorder
    CHAPTER FIVE Natriuretic Peptides in Anxiety and Panic Disorder T. Meyer*,†,1, C. Herrmann-Lingen*,† *University of Gottingen€ Medical Centre, Gottingen,€ Germany †German Centre for Cardiovascular Research, University of Gottingen,€ Gottingen,€ Germany 1Corresponding author: e-mail address: [email protected] Contents 1. Neuroendocrine Factors in Anxiety and Fear-Related Disorders 131 2. Molecular Mechanisms Involved in Natriuretic Peptide Synthesis 132 3. Expression of Natriuretic Peptides and Their Receptors in the Brain 135 4. Physiological Actions of Natriuretic Peptides in the Brain 138 5. Neuroprotective Effects of Natriuretic Peptides 139 6. Evidence of Anxiolytic-Like Effects of ANP 140 References 142 Abstract Natriuretic peptides exert pleiotropic effects on the cardiovascular system, including natriuresis, diuresis, vasodilation, and lusitropy, by signaling through membrane-bound guanylyl cyclases. In addition to their use as diagnostic and prognostic markers for heart failure, accumulating behavioral evidence suggests that these hormones also modulate anxiety symptoms and panic attacks. This review summarizes our current knowledge of the role of natriuretic peptides in animal and human anxiety and highlights some novel aspects from recent clinical studies on this topic. 1. NEUROENDOCRINE FACTORS IN ANXIETY AND FEAR-RELATED DISORDERS Anxiety and fear-related disorders, such as generalized anxiety disor- der, panic disorder, agoraphobia, and specific and social phobia, are clinically well-studied conditions characterized by an unpleasant state of inner tension and the expectation of future threat. The nosological entities subsumed under the rubric anxiety and fear-related disorders are usually accompanied by a variety of somatic symptoms, such as sweating, autonomic dysfunction, altered heart rate, abdominal distress, and nausea.
    [Show full text]
  • Vasopressin Generates a Persistent Voltage-Dependent Sodium Current in a Mammalian Motoneuron
    The Journal of Neuroscience, June 1991, 1 f(6): 1609-l 616 Vasopressin Generates a Persistent Voltage-dependent Sodium Current in a Mammalian Motoneuron Mario Raggenbass, Michel Goumaz, Edoardo Sermasi, Eliane Tribollet, and Jean Jacques Dreifuss Department of Physiology, University Medical Center, CH-1211 Geneva, Switzerland During the period of life that precedes weaning, the facial diographical, and biochemical studies have suggestedthat nucleus of the newborn rat is rich in 3H-vasopressin binding vasopressinprobably also plays a role as a neurotransmitteri sites, and exogenous arginine vasopressin (AVP) can excite neuromodulator (Audigierand Barberis, 1985; Buijs, 1987; Du- facial motoneurons by interacting with V, (vasopressor-type) bois-Dauphin andzakarian, 1987;Van Leeuwen, 1987; Freund- receptors. We have investigated the mode of action of this Mercier et al., 1988; Poulin et al., 1988; Tribollet et al., 1988), peptide by carrying out single-electrode voltage-clamp re- and on the basisof behavioral studies, it has been claimed that cordings in coronal brainstem slices from the neonate. Facial this peptide may influence memory storage and retrieval (De motoneurons were identified by antidromic invasion follow- Wied, 1980). Electrophysiological studies have indicated that ing electrical stimulation of the genu of the facial nerve. vasopressincan directly excite selected populations of central When the membrane potential was held at or near its resting neurons (Suzue et al., 1981; Miihlethaler et al., 1982; Ma and level, vasopressin generated an inward current whose mag- Dun, 1985; Peters and Kreulen, 1985; Raggenbasset al., 1987, nitude was concentration related; the lowest peptide con- 1988, 1989; Carette and Poulain, 1989; Liou and Albers, 1989; centration still effective in eliciting this effect was 10 nM.
    [Show full text]
  • Peptoid Morphology Studies and Its Performance in Inhibiting Islet Amyloid Polypeptide Dongwon Park
    University of Arkansas, Fayetteville ScholarWorks@UARK Chemical Engineering Undergraduate Honors Chemical Engineering Theses 5-2016 Peptoid morphology studies and its performance in inhibiting islet amyloid polypeptide Dongwon Park Follow this and additional works at: http://scholarworks.uark.edu/cheguht Recommended Citation Park, Dongwon, "Peptoid morphology studies and its performance in inhibiting islet amyloid polypeptide" (2016). Chemical Engineering Undergraduate Honors Theses. 87. http://scholarworks.uark.edu/cheguht/87 This Thesis is brought to you for free and open access by the Chemical Engineering at ScholarWorks@UARK. It has been accepted for inclusion in Chemical Engineering Undergraduate Honors Theses by an authorized administrator of ScholarWorks@UARK. For more information, please contact [email protected], [email protected]. Peptoid morphology studies and its performance in inhibiting islet amyloid polypeptide Dongwon Park University of Arkansas, Fayetteville May 2016 Table of Contents 1. Introduction 1.1 Misfolded proteins............................................................................................................1 1.1.1 Alzheimer disease (Amyloid beta)..................................................................2 1.1.2 Type 2 diabetes (Amylin) ..............................................................................4 1.2 What is Peptoid ?..............................................................................................................5 2. Previous Research on Misfolded proteins 2.1
    [Show full text]
  • Influence of Cholesterol on Human Calcitonin Channel Formation
    AIMS Biophysics, 6(1): 23–38. DOI: 10.3934/biophy.2019.1.23 Received: 31 October 2018 Accepted: 24 January 2019 Published: 01 February 2019 http://www.aimspress.com/journal/biophysics Research article Influence of cholesterol on human calcitonin channel formation. Possible role of sterol as molecular chaperone Daniela Meleleo* and Cesare Sblano Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari “Aldo Moro”, via E. Orabona 4, 70126 Bari, Italy * Correspondence: Email: [email protected] ; Tel: +390805442775. Abstract: The interplay between lipids and embedded proteins in plasma membrane is complex. Membrane proteins affect the stretching or disorder of lipid chains, transbilayer movement and lateral organization of lipids, thus influencing biological processes such as fusion or fission. Membrane lipids can regulate some protein functions by modulating their structure and organization. Cholesterol is a lipid of cell membranes that has been intensively investigated and found to be associated with some membrane proteins and to play an important role in diseases. Human calcitonin (hCt), an amyloid-forming peptide, is a small peptide hormone. The oligomerization and fibrillation processes of hCt can be modulated by different factors such as pH, solvent, peptide concentration, and chaperones. In this work, we investigated the role of cholesterol in hCt incorporation and channel formation in planar lipid membranes made up of palmitoyl- oleoyl-phosphatidylcholine in which no channel activity had been found. The results obtained in this study indicate that cholesterol promotes hCt incorporation and channel formation in planar lipid membranes, suggesting a possible role of sterol as a lipid target for hCt. Keywords: cholesterol; Human calcitonin; lipid-peptide interaction; planar lipid bilayer; ion channel 1.
    [Show full text]
  • Practice Problems on Amino Acids and Peptides
    AA.1 Practice Problems on Amino Acids and Peptides 1. Which one of the following is a standard amino acid found in proteins? a) CH2 c) Ph e) NH COOH CH2 CH2OH 2 CH 2 CH COOH CH COOH (CH3)2N H2N b) CH3 CH SO3H d) NH2 N COOH 2. Which one of the following amino acids is least likely to be naturally occurring? CO2 O2CNH3 CH2CH2SCH3 CH2SH H3N CO2 H NH3 H NH3 HSH2CH H3N H CH2SH CO2 H CH2CH2SCH3 CO2 AB C D E 3. Amino acids are amphoteric. Which statement best describes the definition of the term amphoteric? A) Amino acids exist as a zwitterion in the solid state B) Amino acids possess both acidic and basic functional groups C) An aqueous solution of an amino acid will conduct electricity D) Amino acids are soluble in water E) Amino acids are colourless AA.2 4. Ninhydrin reacts with most -amino acids to produce a purple compound. Which structure is not reasonably involved in the formation of the compound? O R OH A N CO2 C NH2 O O E O NH2 O O OH R O B N N D N O O O 5. All but one of the natural amino acids react with ninhydrin (I) to give a purple pigment (II). Which one of the five listed will not react with ninhydrin to give II? O O O O N O O O III Asp Cys Met Pro Leu 6. In order to work out the structure of a protein, a necessary first step is to analyze for the amounts of each amino acid contained in it.
    [Show full text]
  • The Action of Morphine Which Increases Gastric
    A COMPARATIVE STUDY ON THE MECHANISM OF ACTION OF MORPHINE ON GASTRIC ACID SECRETION IN DOGS Isamu YAMAGUCHI Research Laboratories, Fujisawa Pharmaceutical Co. Ltd, Yodogaxwa-ku, Osaka, Japan Accepted July 23, 1974 Abstract-While researching the mechanisms of gastric secretagogue action of mor phine, the effects of hexamethonium, atropine and secretin on morphine-induced gastric secretion were studied, and were compared with those on food-, histamine and tetrapeptide-induced gastric secretion in conscious dogs, and on histamine-, tetrapeptide and bethanecol-induced gastric secretion in anesthetized dogs. Effect of acute bilateral vagotomy on the gastric secretion was also investigated in anes thetized dogs. Results are discussed in relation to the mechanisms involved in the stimulation and inhibition of gastric secretion, and the following suggestions are made. Direct vagal excitation of oxyntic glands and endogenous gastrin plays an important role in food-induced secretion in innervated and denervated fundic pouches, respectively. Exogenous gastrin stimulates gastric secretion activating cholinergic post-ganglionic nerve fibers in conscious dogs. In anesthetized dogs, however, exogenous gastrin induces its secretagogue action mainly by a direct action on oxyntic glands. A close similarity was observed between morphine-induced se cretion and food-induced secretion in denervated fundic pouches when inhibitory activities of drugs were compared. It is thus concluded that endogenous gastrin plays an important role in the gastric secretion induced by morphine. The action of morphine which increases gastric secertion was first reported by Riegel (1) as early as in 1900 and it was later shown by Smirnov and Schirokij (2) that this in crease is achieved by way of the vagus nerve.
    [Show full text]
  • Cyclic Natriuretic Peptide Constructs Cyclische Natriuretische Peptidkonstrukte Constructions De Peptides Natriurétiques Cycliques
    (19) TZZ ZZ___T (11) EP 2 001 518 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: (2006.01) of the grant of the patent: A61K 38/10 10.07.2013 Bulletin 2013/28 (86) International application number: PCT/US2007/065645 (21) Application number: 07759833.2 (87) International publication number: (22) Date of filing: 30.03.2007 WO 2007/115175 (11.10.2007 Gazette 2007/41) (54) CYCLIC NATRIURETIC PEPTIDE CONSTRUCTS CYCLISCHE NATRIURETISCHE PEPTIDKONSTRUKTE CONSTRUCTIONS DE PEPTIDES NATRIURÉTIQUES CYCLIQUES (84) Designated Contracting States: (74) Representative: Van Breda, Jacobus et al AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Octrooibureau Los & Stigter B.V., HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE Weteringschans 96 SI SK TR 1017 XS Amsterdam (NL) Designated Extension States: AL BA HR MK RS (56) References cited: EP-A- 0 223 143 (30) Priority: 30.03.2006 US 743960 P 30.03.2006 US 743961 P • LI BING ET AL: "Minimization of a polypeptide hormone" SCIENCE (WASHINGTON D C), vol. (43) Date of publication of application: 270, no. 5242, 1995, pages 1657-1660, 17.12.2008 Bulletin 2008/51 XP002547160 ISSN: 0036-8075 • DUTTAA.S. JOURNAL OF PEPTIDE SCIENCE vol. (73) Proprietor: Palatin Technologies, Inc. 6, 2000, pages 321 - 341, XP002564522 Cranbury, NJ 08512 (US) • DE VISSER P.C.J.: ’Solid-phase synthesis of polymyxin B1 and analogues via a safety-catch (72) Inventors: approach’PEPTIDE RES. vol. 61, no. 6, June 2003, • SHARAMA, Shubh, D. pages 298 - 306, XP002389978 Cranbury, NJ 08512 (US) • BASTOS, Margarita Remarks: Plainsboro, NJ 08536 (US) Thefile contains technical information submitted after • YANG, Wei the application was filed and not included in this Edison, NJ 08820 (US) specification • CAI, Hui-zhi East Brunswick, NJ 08816 (US) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 5,434,246 Fukuda Et Al
    US005434246A United States Patent (19) 11 Patent Number: 5,434,246 Fukuda et al. 45 Date of Patent: Jul.18, 1995 Biochemistry, 17(16):3188-3191 (1978). 54 PARATHYROID HORMONEDERIVATIVES F. Cohen et al., The Journal of Biological Chemistry, 75) Inventors: Tsunehiko Fukuda, Kyoto; Shizue Nakagawa; Shigehisa Taketomi, both 266(3):1997-2004 (1991). of Osaka, all of Japan Primary Examiner-Howard E. Schain Assistant Examiner-Phynn Touzeau 73) Assignee: Takeda Chemical Industries, Ltd., Attorney, Agent, or Firm-David G. Conlin; Peter F. Osaka, Japan Corless (21) Appl. No.: 33,099 57 ABSTRACT 22 Filed: Mar. 16, 1993 Parathyroid hormone (PTH) derivatives represented by (30) Foreign Application Priority Data the general formula: Mar. 19, 1992 JP Japan .................................. 4-063517 Ser-Val-R1-Glu-Ile-Gln-Leu-Met-His-Asn-Leu Feb. 18, 1993 JP Japan .................................. 5-029283 Gly-Lys-R2-Met-Glu-Arg-Val-Glu-Trp-Leu-R3 51) Int. Cl......................... C07K 14/00; C07K 4/00; Leu-Gln-Asp-Val-His-Asn-R4 A61K 38/23 52 U.S. Cl. .................................................... 530/324 or a salt thereof, wherein R1 represents Ser or a D-a- 58) Field of Search ............... 530/324;930/DIG. 10; amino acid residue of 4 or less carbon atoms; 514/12 R2 represents a tetrapeptide chain which contains at 56) References Cited least one water-soluble a-amino acid residue; U.S. PATENT DOCUMENTS R3 represents a tripeptide chain which contains at least one water-soluble d-amino acid residue; and 4,086, 196 4/1978 Tregear ............................... 530/324 4,086,198 4/1978 Tregear ............................... 530/324 R4 represents an aromatic amino acid residue or an 4,656,250 4/1987 Morita et al.
    [Show full text]
  • 18.4 Peptides 559
    18.4 Peptides 559 18.4Peptides AIMS: Tonome ond describethe bond thot linksomino ocids together.To drow completestructirol formulos for simple peptides.To controstthe biologicol functionsof some peptide hormones. A peptide is any combination of amino acids in which the alpha amino Focus group (-NH) of one acid is united with the alpha carboxylic group Amino acids are linked to form (-CO2H) of another through an amide bond. peptides. RO RO til ril H2N-C-C-OH + H-N-C-C-OH ------- I H HH Amino acid Amino acid RO RO til ttl H2N-C-C-N-C-C-OH + H2O ttt H HH Peptide The amide bonds formed in peptides always involve the alpha amino and alpha carboxylic acid groups and never those of side chains. More amino acids maybe added in the same fashion to form chains such as those in Figure l9.l. The amide bond between the carbonyl group of one amino acid and the nitrogen of the next amino acid in the peptide chain is called a peptide bond, or peptide link. Amino acids that haue been incorporated into peptides are called amino acid residues. As more amino acid residues are added, a backbone common to all peptide molecules is formed. The amino acid residue with a free amino group at one end of the chain is the N-termi- nal residue:the residue with a free carboxvlic acid at the other end of the chain is the C-terminal residue.The number of amino acid residuesin a peptide is often indicated by a set of preflxes for peptides of up to l0 C-terminal residue Figutel8.l Partsof a peptide-in this case,a tetrapeptide.The peptide bonds of the zigzagbackbone are shown in color.Note that the C-terminalis at the right and the N-terminqlis at the left.
    [Show full text]